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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, whose main molecular trait is the MAPK pathway
activation due to KRAS mutation, which is present in 90% of cases.
The genetic landscape of KRAS wild type PDAC can be divided into three categories. The first is represented by
tumors with an activated MAPK pathway due to BRAF mutation that occur in up to 4% of cases. The second
includes tumors with microsatellite instability (MSI) due to defective DNA mismatch repair (dMMR), which occurs in
about 2% of cases, also featuring a high tumor mutational burden. The third category is represented by tumors
with kinase fusion genes, which marks about 4% of cases. While therapeutic molecular targeting of KRAS is an
unresolved challenge, KRAS-wild type PDACs have potential options for tailored treatments, including BRAF
antagonists and MAPK inhibitors for the first group, immunotherapy with anti-PD-1/PD-L1 agents for the MSI/dMMR
group, and kinase inhibitors for the third group.
This calls for a complementation of the histological diagnosis of PDAC with a routine determination of KRAS
followed by a comprehensive molecular profiling of KRAS-negative cases.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is the sev-
enth leading cause of global cancer-related deaths in in-
dustrialized countries, projected to become the second
most common in the next decade worldwide [1–3].
More than 80% of PDAC patients present with locally
advanced or metastatic disease, not amenable to surgical
resection with curative intent, at the time of diagnosis
[3, 4]. Despite progress in the chemotherapeutic treat-
ment of PDAC, long-term survival remains dismal, with
less than 10% of patients alive 5 years after diagnosis [5,
6]. To improve PDAC survival significantly, new thera-
peutic strategies are needed. One of the most promising
tools is represented by the integration of histology with
molecular pathology, to identify potential molecular tar-
gets for tailored treatments [7].
From a genetic point of view, PDAC is a composite
disease, showing a very complex network of point muta-
tions, epigenetic alterations and chromosomal structural
variants [8, 9]. Within this complexity, however, the
master driver is the KRAS (Kirsten rat sarcoma) onco-
gene [8–10], mutationally activated in over 90% of cases
and recently reported to be more common in older (≥50
years) and female patients [11]. Notably, KRAS muta-
tions can be detected with reliable sensitivity and specifi-
city also through liquid biopsy in PDAC patients [12].
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KRAS encodes a small GTPase, which acts as a
transducer-effector, cooperating with cell surface recep-
tor tyrosine kinases [10]. Once triggered, it activates dif-
ferent intracellular pathways involved in carcinogenesis,
such as proliferation and cell migration, evasion of the
immune system, and block of apoptosis [10]. Among the
different pathways interrelating with KRAS function, the
mitogen-activated protein kinase (MAPK) pathway is a
crucial one [8–10].
Although many therapeutic efforts have been made to
target the function of mutated KRAS oncoprotein, they
have been unsuccessful in substantially modifying PDAC
prognosis. For example, three recent phase 2 trials evalu-
ated MAPK inhibitors alone or in combination with
gemcitabine in locally advanced and/or metastatic
PDAC, and failed to show any survival benefit [13–16].
Other efforts include 4 studies that evaluated KRAS vac-
cines in PDAC patients: three studies that looked at RAS
peptide vaccines and one that used GI-4000, a tarmogen
(targeted molecular immunogen) designed to target cells
with mutant KRAS [17–21]. Furthermore, the targeted
drug tipifarnib that inhibits the Ras-dependent growth
of cancer cells was tested in a large phase 3 trial and a
phase 1 dose escalation trial in combination with gemci-
tabine in advanced PDAC [22, 23]. However, none of
these studies achieved significant survival benefits in
PDAC patients. Notably, a recent report regarding extra-
cellular signal-regulated kinases (ERK) in KRAS-mutated
PDAC, based on cell lines, pancreatic cancer organoids,
and xenograft mouse-models, showed that ERK inhib-
ition in cancer-associated stromal cells can suppress
cancer-stromal interactions and PDAC metastatic poten-
tial [24]. Along these lines, Sun and colleagues, reported
that inhibition of the phosphorylation of transgelin-2, a
novel target of KRAS-ERK signaling, may be a potential
therapeutic strategy for targeting PDAC with KRAS mu-
tation, using PDAC cell lines, immunohistochemistry on
PDAC tissues, and xenograft-mouse models [25]. Al-
though promising, such findings are exploratory and still
without a direct clinical translation. These points high-
light the difficulties in targeting KRAS, and this situation
still represents one of the most important reasons that
can explain the high-mortality rate of PDAC also in the
era of precision oncology [10, 26]. Moreover, Kim and
colleagues reported that PDAC patients with KRAS mu-
tations display a worse response to gemcitabine-based
chemotherapy and shorter overall survival than those
with KRAS wild-type [27]. Along the same lines, Windon
and colleagues confirmed a survival disadvantage for
KRAS mutant patients, showing that such adverse prog-
nostic effect was independent of mismatch repair status
and the specific chemotherapy regimen employed [28].
These findings warrant further investigation, as they
may support new strategies for implementing precision
oncology in PDAC patients. For example, using a spe-
cific gene signature for KRAS dependency, recently led
to the identification and validation of decitabine as a po-
tent inhibitor of growth in KRAS-dependent pancreatic
cancer cells and patient-derived xenograft models [29],
an approach that is now being translated to the clinic.
Intriguingly, a not-negligible proportion of PDAC (about
8–12%) does not harbor KRAS mutations [3, 8, 9, 11]. The
definition of the genetic landscape of KRAS wild-type
PDAC has been recently improved by whole-genome se-
quencing studies [8, 11], which highlighted the occurrence
of several genetic alterations representing potential targets
for tailored therapy. At this time, KRAS wild-type tumors
are the molecular PDAC subgroup that might receive the
highest prognostic benefits from precision oncology.
Molecular pathology and therapeutic
opportunities
The genetic landscape of KRAS-wild type PDAC can be
subdivided into three different groups: i) PDAC with the
presence of an activated-MAPK in the absence of a
KRAS mutation, ii) PDAC with microsatellite instability/
defective DNA mismatch repair, and iii) PDAC with
kinase-fusion genes. These alterations dominate the
KRAS wild type PDAC genetic landscape, and occur in
different proportions (Fig. 1). This review will focus on
molecular pathology and therapeutic opportunities in
these specific PDAC molecular settings.
The MAPK pathway and the role of BRAF (B-Raf proto-
oncogene)
The MAPK pathway is the most important core signal-
ing pathway in PDAC [3, 8, 9, 11, 26], in which the acti-
vation of RAS is a crucial step. Such activation is
mediated by a guanine nucleotide exchange factor [30].
Active RAS is self-inactivated by intrinsic GTPase activ-
ity, based on a GTPase-activating protein [31]. KRAS
mutations in PDAC often involve codons 12, 13 and 61;
most of them are G12D or G12R substitutions, which
decrease the intrinsic GTPase activity, thus resulting in
prolonged activation of RAS [31].
Notably, the activation of MAPK pathway is possible
also in the absence of KRAS mutations [30]. A recent
study by Singhi et al. definitively demonstrated that the
MAPK signaling is activated in about one third of KRAS
wild-type PDAC [11]. In this cohort, BRAF alterations
were the most prevalent, and included activating mis-
sense mutations, amplification and kinase fusions. BRAF
mutations were mutually exclusive with those of KRAS;
furthermore, kinase fusions in BRAF were not present in
KRAS mutant cases [11]. BRAF encodes for the B-
RAF proto-oncogene, a serine/threonine kinase belong-
ing to a family of MAPK kinases [30]. The most com-
mon mutations in BRAF usually involve codon 600 and
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often results in a V600E substitution, leading to consti-
tutive activation of its kinase function, which is the re-
sults also of the other aforementioned alterations [32,
33]. The mutual exclusivity of KRAS and BRAF muta-
tions in PDAC suggests that the activating mutations of
these genes can compensate for each other in PDAC
oncogenesis via activation of the MAPK pathway [30].
Recent data also suggest that other molecular alterations
may modulate cancer cell (including PDAC) susceptibil-
ity to MAPK inhibition: indeed, PTEN loss was shown to
portend intrinsic resistance to MEK inhibitors and syn-
ergistic activity of combined MAPK/phosphatidylinositol
3 kinase (PI3K) pathway inhibition [34]; however, com-
bined MAPK/PI3K inhibition did not prove effective in
either cell line models of PDAC [35] or PDAC patients
[36], presumably owing to the lack of PTEN alterations.
B-RAF is immediately downstream of RAS and triggers
MAP2K1/MEK, which activates MAPK1/ERK2, import-
ant mediators of the MAPK pathway. Then, the activat-
ing signal is passed on by a chain of kinase reactions,
overall establishing MAPK signaling pathway [30]. Con-
sequently, activating mutations of KRAS and BRAF pro-
duce at last the activation of this pathway, which is
crucial for pancreatic cancer (Fig. 2). Interestingly,
MAPK kinases are classified into three classes based on
their distinctive effectors: extracellular signal-regulated
kinases (ERK), Jun amino-terminal kinases (JNK) and
p38-mitogen-activated protein kinases (p38MAPK) [37].
Each class regulates distinct functions: ERK is involved
in proliferation, JNK in apoptosis and differentiation and
p38MAPK in stress responses [37]. To enact specific cell
responses, activated MAPK kinases translocate into the
nucleus, where, through phosphorylation of different
transcription factors, they can directly modulate the ex-
pression of different genes [30, 38]. Additional mecha-
nisms that may replace KRAS/BRAF function for RTK/
RAS/MAPK activation included mutations or amplifica-
tions of GNAS, EGFR, ERBB2, MET, ERBB3 and FGFR2
[9].
Regarding therapeutic approaches to MAPK pathway
targeting, in addition to the above described MAPK in-
hibitors, some other interesting data come from a large,
multicenter, non-randomized trial of 581 PDAC pa-
tients, as part of the so-called “Know Your Tumor” ini-
tiative [39]. In this cohort, wild-type KRAS tumors
accounted for 8% of the whole PDAC cohort, and a sig-
nificant proportion (24%) of these had alterations in
other MAPK pathway effectors, including BRAF activat-
ing alterations. In this setting, patients who received mo-
lecular target therapy, including MAPK inhibitors and
BRAF-targeted drugs, achieved an improved
progression-free survival and median overall survival
[38]. Other data regarding direct BRAF inhibitors come
from a recent study, which reported a 6-months remis-
sion of a BRAF- mutant PDAC patient treated with the
inhibitor dabrafenib [40]. Moreover, preclinical data in-
dicate that even wt-BRAF might constitute a suitable
therapeutic target in PDAC, taking advantage of the
therapeutic synergism of “vertical” combination strat-
egies simultaneously targeting BRAF and MEK along the
same pathway, regardless of KRAS mutational status
[41].
From the point of view of molecular pathology, an im-
portant consideration regards the specific BRAF muta-
tion to be encountered in PDAC. Indeed, mutations that
are the most common in other tumor types, including
Fig. 1 The genetic landscape of KRAS wild-type pancreatic ductal adenocarcinoma (PDAC) is shown. The vast majority of cases harbored KRAS
mutations, but about 8–10% of cases show other molecular alterations, including microsatellite instability (MSI) – high tumor mutational burden
(hTMB), kinase fusion genes, and activation of the MAPK pathway without KRAS involvement
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melanoma and thyroid carcinoma, are not frequently
present in PDAC. Singhi and colleagues [11] reported
typical V600E and V600K BRAF mutations in only about
1/5 of PDAC with BRAF alterations. This point requires
the adoption of next-generation sequencing (NGS) tech-
nologies in clinical practice to guarantee in-depth ana-
lysis of the coding regions of BRAF, coupled with the
possibility to investigate other BRAF alterations, such as
the presence of fusion genes.
Microsatellite instability (MSI) / defective mismatch repair
(dMMR)
Another genetic alteration enriched in KRAS wild-type
PDAC is microsatellite instability (MSI)/defective mis-
match repair (dMMR) [11, 42–45]. A recent study has
definitively demonstrated that MSI/dMMR PDAC harbor
KRAS mutations less frequently than conventional PDAC,
reaching statistically significant values [42]. However, it
should be acknowledged that about one third of MSI/
dMMR PDAC can present KRAS mutations [43, 44].
Microsatellites are short, repetitive DNA sequences of 1–6
base pairs present throughout the genome, mostly in non-
coding regions [35]. Their repetitive nature renders them
very sensitive to DNA mismatching errors, which can
occur during DNA replication or iatrogenic damage [45].
Cancers harboring a dMMR are very often hypermutated
and typically accumulate mutations in microsatellites: this
condition is termed MSI [45].
The MSI phenotype was first described in the familial
cancer condition known as Lynch syndrome (LS), where
Fig. 2 A schematic representation of the MAPK pathway is here shown. As highlighted, B-RAF is an immediately downstream of RAS and triggers
MAP 2 K1/MEK, which activates MAPK1/ERK2, important mediators of the entire MAPK pathway. The overall effects include block of apoptosis,
stress response and cell proliferation
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the MMR genes MLH1, MSH2, MSH6 or PMS2 harbor
germline mutations and portend marked susceptibility
to develop several types of cancer, including PDAC [43].
MSI can be tested using immunohistochemistry (IHC)
and molecular tests, including classic polymerase chain
reaction (PCR) and next-generation sequencing (NGS)
[45–47]. Immunohistochemical analysis is more reliable
for cancers belonging to the spectrum of LS [43], where
the loss of expression of the heterodimers MLH1-PMS2
and/or MSH2-MSH6 represent a very reliable surrogate
of dMMR [44, 45]. For other cancer types, PCR or NGS
approaches appear more robust for MSI/dMMR assess-
ment and should be used instead of IHC. In PDAC, the
use of IHC appears a reliable method (Fig. 3), although
this cancer type does not represent one of the most
common malignancies in LS patients [44, 45].
MSI in PDAC has been described with variable fre-
quencies, with a prevalence ranging approximatively
from 0.1 to 7% in the most recent investigations on large
cohorts of patients [30, 48–51]. However, a recent com-
prehensive seminal paper has established its prevalence
in PDAC at around 1–2% [44]. Highest values of MSI
prevalence have been reached in specific PDAC sub-
types, such as medullary variant, mucinous/colloid vari-
ant and IPMN-derived carcinomas [40, 44, 51]. Among
conventional PDAC, Humphris et al., who interrogated
385 pancreatic cancer genomes for mutational signatures
inferring defects in DNA repair, identified MSI in 1% of
tumors [48]. Along this line, Hu et al., using an NGS
assay designed to perform targeted deep sequencing of
cancer-associated genes, found a 0.8% MSI frequency in
a cohort of 833 PDAC [50]. Although it is a rare condi-
tion, the new frontiers of immunotherapy have opened
new important therapeutic opportunities for tumors
with this molecular alteration. Indeed, because of the de-
fective mismatch repair machinery, tumors with MSI are
hypermutated neoplasms; this genetic alteration leads to
the synthesis of several (up to 50 times more than
microsatellite stable tumors) aberrant and potentially
immunogenic neo-antigens by the tumor cells [52]. An
important self-response to the presence of these neo-
antigens is a diffuse infiltration of the tumor area by
cytotoxic T-cell lymphocytes (CTLs) [52]. Recent studies
have highlighted the concomitant expression of multiple
Fig. 3 This is a classic example of a conventional pancreatic ductal adenocarcinoma (PDAC) with microsatellite instability, assessed by
immunohistochemistry. a An infiltrating PDAC gland is centrally located on the left (arrow), and a normal endocrine islet is on the right (asterisk).
Hematoxylin-Eosin staining, original magnification X10. b Loss of expression of the MMR protein MLH1 with immunohistochemistry. The
infiltrating PDAC gland is totally negative (loss of protein expression), and the same time the endocrine cells of the islet are positive, as well as
lymphocytes, endothelial and stromal cells in the periphery (the expression of the MMR proteins in non-neoplastic cells is used as an internal
control demonstrating the reliability of the immunohistochemical analysis). Original magnification X10. c, d Conserved expression of the MMR
proteins MSH2 (c) and MSH6 (d). Original magnification X10. e Loss of expression of the MMR protein PMS2 with immunohistochemistry. The
infiltrating gland is totally negative (loss of expression), and the same time the endocrine cells of the islet as well as lymphocytes, endothelial and
stromal cells in the periphery are positive. Original magnification X10
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active immune checkpoint markers, such as the Pro-
grammed Cell Death Protein 1 (PD-1) and its ligand PD-
L1. Their interaction cause T cells functional exhaustion
and unresponsiveness [53]. Based on this discovery, Le
et al. evaluated in 2015 the clinical activity of pembrolizu-
mab, an anti-PD-1 immune checkpoint inhibitor, in a co-
hort of metastatic colorectal and non-colorectal
carcinoma patients with or without MSI [54]. However,
no patient with PDAC was included in this study. The re-
sults of this phase 2 trial clearly showed that MSI status
was able to predict clinical benefits from immune check-
point blockade therapy with pembrolizumab [55, 56]. In
2017, the same group published the “KEYNOTE-158”
trial, investigating PD-1 blockade efficacy in patients with
advanced dMMR cancers across different tumor types, in-
cluding also PDAC [57]. If initially the objective response
rate was similar between colorectal versus other tumor
subtypes, an update of the trial including a total of 22
MSI/dMMR PDAC patients, showed only 4 of 22 patients
with objective responses, which represented the lowest ob-
jective response among the different cancers investigated
[58]. These findings highlight the complex biology of
PDAC and call for further investigations in this field.
Of interest, tumor mutational burden (TMB) is an-
other important variable in this setting, since it has been
strictly correlated to the response to immunotherapy.
TMB is a value that represents the rate of mutations in a
tumor, and is expressed as the number of mutations per
megabase. In PDAC, a high TMB is a rare finding and
very often occurs simultaneously with MSI [11, 47, 50].
New NGS approaches can provide simultaneously data
on MSI and TMB, with potentially immediate conse-
quences on therapeutic opportunities for these specific
PDAC molecular subgroups.
From the point of view of molecular pathology, it is
important to acknowledge that IHC, performed using
the antibodies for all 4 MMR proteins (MLH1, PMS2,
MSH2 and MSH6) represents a very reliable method-
ology to assess MSI in PDAC. However, in cases of
doubtful IHC results, MSI/dMMR should be assessed
with PCR-based MSI or NGS. In cases with limited tis-
sue (e.g.: endoscopic/ultrasound guided fine needle bi-
opsy), NGS should be adopted as the first choice, as
highlighted by a recent study on this topic [44]. Due to
the potential importance associated with a diagnosis of
MSI/dMMR in the context of PDAC, including eligibility
for immunotherapy trials, it is of primary importance
that all methodologies for MSI/dMMR assessment fol-
low standardized protocols (including all pre-analytical
phases) and up to date recommendations [45].
Kinase fusion genes
The most important original report on this topic is a re-
cent massive sequencing-based paper with a cohort of
3594 PDAC, where Singhi et al. showed that kinase fu-
sion genes are one of the most frequent putative driver
alterations in KRAS wild-type PDACs [11]. They found
specific kinase fusions in FGFR2 (12 cases), RAF (7
cases), ALK (5 cases), RET (4 cases), MET (2 cases),
NTRK1 (2 cases), ERBB4 (1 case) and FGFR3 (1 case),
representing about 7.6% of genetic alterations of all
KRAS wild-type PDAC. In the majority of fusion genes,
a serine/threonine kinase or tyrosine kinase catalytic do-
main was fused to an oligomerization domain, which
may represent a mutual mechanism of activation [11].
All these kinase fusions were mutually exclusive and,
similar to BRAF, they were not present in PDACs with
KRAS alterations [11].
Regarding the therapeutic approach to PDAC patients
with kinase fusions, there are still limited data in the lit-
erature. Interestingly, a previous research identified 4
PDAC patients with ALK fusions; 3 of them showed
stable disease with normalization of serum CA19-9
levels after treatment with an ALK inhibitor [59]. Not-
ably, Pishvaian et al. recently described 2 PDAC patients
with NTRK1 fusions; such patients were already meta-
static at the time of diagnosis but showed partial re-
sponses to the specific targeted drug entrectinib [60].
Regarding BRAF and RAF fusions, these molecular alter-
ations have not been described in PDAC but in another
exocrine pancreatic cancer, which is acinar cell carcin-
oma [61]. Intragenic/in-frame deletions in BRAF repre-
sent other potential driver alterations in KRAS wild-type
PDAC. Although also in this case there are limited data,
Aguirre et al. reported a single PDAC patient with onco-
genic BRAF deletion with response to the pathway in-
hibitor trametinib [62].
In the last few years, several studies have detected neur-
egulin 1 (NRG1) fusion genes across different cancer
types, particularly in invasive mucinous adenocarcinoma
(IMA) of the lung and PDAC. Moreover, NRG1 fusions
have been detected with several fusion partners [63]. The
NRG1 gene encodes for a member of the epidermal
growth factor (EGF) family, which binds to ERBB3,
thereby causing its heterodimerization with ERBB2. NRG1
gene fusions are generally in-frame and generate fusion
proteins that maintain the extracellular EGF domain of
NRG1 and the transmembrane domain of the rearrange-
ment partner. Thus, the EGF domain of the fusion protein
can constitutively bind to its partner and activate signaling
through MAPK, PI3K-AKT, and NF-kB, increasing tumor
proliferation and survival [63, 64]. In patients affected by
PDAC, NRG1 fusions are detected only in KRAS wild-type
tumors and usually in the absence of other concomitant
driver gene mutations, suggesting that the rare NRG1 fu-
sions act as an oncogenic driver in this tumor. In addition,
some studies have demonstrated the actionability of
NRG1 fusions in PDAC. Indeed, when patients affected by
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Table 1 Selected trials targeting molecular aberrations enriched in KRAS-wt PDAC
Target Tested drug Phase trial Population Primary Outcomes
ALK ceritinib Phase I
NCT02227940
Dose escalation (ALK negative) and expansion
cohort (ALK positive) in advanced solid tumors
in combination with standard chemotherapy
Expansion cohort 2E: advanced pancreatic







Pancreatic cancer BRAF mutated (V600E) after










Diagnosis of pancreatic cancer (resectable,
borderline resectable, or advanced) are eligible




Pretreated Advanced Pancreatic Cancer
Assess the feasibility of collecting tumor
tissue for biomarker evaluation prior to









Solid tumors RET activated









Solid tumors with NTRK1/2/3, ROS1, ALK gene
rearrangments
ORR
NTRK VDM-928 Phase I
NCT03556228
Expansion phase:







advanced solid tumors harboring ROS1 or NTRK1,






Dose escalation (NRG1 negative) and dose
expansion (NRG1 positive) in advanced solid tumors






HER2 A116 Phase I/II
NCT03602079
Relapsed/Refractory Cancers Expressing HER2











cohort six: patient with no satisfactory alternative
treatment option affected by advanced pancreatic






Phase I: pretreated solid tumor













Dose escalation cohorts: histologically confirmed
advanced refractory solid tumor
MTD
Expansion: metastatic pancreatic cancer patients OS
MSI dostarlimab Phase I
NCT02715284
Part 2B: Cohort F non-endometrial dMMR/MSI-H
or POLE-Mutated solid tumors, that have
progressed following up to 2 prior lines of
systemic for advanced disease
AE
FGFR pemigatinib Phase II
NCT03822117
Cohort A Previously Treated Locally Advanced/
Metastatic or Surgically Unresectable Solid Tumor
Malignancies Harboring Activating FGFR 1–3 fusion
ORR
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heavily pretreated PDAC carrying NRG1 fusion received
matched therapy with afatinib, an irreversible ERBB1–4
inhibitor, clinical benefit and objective responses were
documented [65, 66]. However, Drilon at al recently re-
ported four patients affected by IMA of the lung with
NRG1 fusion that did not respond to afatinib, but showed
an extraordinary clinical response to treatment with a new
monoclonal antibody targeting ERBB3 [67].
From a molecular pathology perspective, the necessity
to identify fusion genes further highlights the import-
ance of introducing NGS into clinical practice. For
PDAC patients, this point represents an urgent need, at
least for KRAS wild-type PDAC. The final pathology re-
port for PDAC should integrate morphology with mo-
lecular pathology, following the model of a next-
generation histopathologic diagnosis [68].
Clinical considerations and conclusions
Therapeutic management of pancreatic cancer remains
an important clinical challenge and a clearly unmet
medical need. With the notable exception of PDAC aris-
ing in the context of germline BRCA1/2 mutations [69],
no effective targeted therapies have been developed for
this deadly disease and no routine molecular pathology
testing is currently indicated at diagnosis. Even worse, in
the past 20 years we have witnessed the failure of an aw-
fully long list of clinical trials testing intriguing and pre-
clinically sound molecularly targeted agents. Among
many methodological faults that prevented the success-
ful transition of many agents/combinations from early
phase trials to phase III documentation of efficacy and
registration [70], the most striking finding is that out of
37 trials involving biological agents, only one employed
a biomarker-based population enrichment strategy. Test-
ing targeted drugs in unselected PDAC populations has
not met with clinical success, leading to a largely avoid-
able waste of time, resources and, most importantly, pa-
tients’ lives. In addition, it may have led to the dismissal
of agents/strategies with potential efficacy in specific
populations of patients. This is the case, using an ex-
ample relevant to the topic discussed in this review, for
the addition of trametinib (a potent allosteric MEK in-
hibitor) to gemcitabine as first-line treatment of
advanced PDAC patients [13]: while ineffective in the
entire (unselected) trial population, it might have bene-
fitted the small (n = 40) population of KRAS wild type
patients, in whom the risk of death was reduced by ap-
proximately 40% by the addition of trametinib, although
with results that did not reach statistical significance
[13].
As discussed here, KRAS-wild type PDAC may repre-
sent a distinct molecular subtype of pancreatic cancer.
The genetic hallmarks in this category are represented
by the presence of an activated MAPK, of MSI/dMMR,
and of kinase-fusion genes in variable proportions. Dif-
ferently from conventional PDAC, if appropriately se-
lected based on their individual genomic and molecular
features, these special PDAC subtypes can be treated
with specific therapeutic strategies (see Table 1 for a list
of selected ongoing trials with agents targeting molecu-
lar aberrations that are enriched in KRAS wild type
PDAC), representing an important step towards the es-
tablishment of precision oncology for patients with pan-
creatic cancer [71]. As exemplified by the recently
reported “Know Your Tumor” initiative experience in
PDAC [72], only a minority of patients might currently
benefit from extended molecular profiling (46 out of
1223–4% - profiled patients received matched therapy in
their experience). That said, the evidences reviewed and
discussed on these topics may call for a complementa-
tion of PDAC histological diagnosis with routine deter-
mination of KRAS mutational status, followed by
comprehensive molecular profiling of KRAS wild-type
cases.
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